17 research outputs found

    Situación laboral de los graduados de la cohorte 2014-2018 de la carrera de turismo sostenible del Recinto Universitario Rubén Darío, UNAN-Managua, periodo 2019-2020

    Get PDF
    El turismo a nivel mundial ha experimentado un rápido desarrollo, este se ha convertido en unas de las principales actividades económicas generadoras de divisas y empleos en la gran mayoría de países, según el índice de competitividad de viajes y turismo del Foro Económico Mundial en el 2017, la industria turística movió US$7.600 millones en el mundo y creó 292 millones de puesto de trabajo en el 2016, en la actualidad es considerada como el primer sector económico a nivel mundial que experimentará un mayor incremento, en cuanto a inversión de capital y generación de trabajo (Travel2LATAM, 2016). El turismo representa 1 de cada 10 empleos a nivel global, la importancia del sector se torna crucial para el futuro de las economías, en el caso de Latinoamérica en los años 2013 y 2015, el número de llegadas internacionales aumentó de 170 a 201 millones de turistas; de estos 90 millones llegaron a América y el Caribe; así mismo, de las 136 economías que representan el 98% del Producto Interno Bruto Mundial (PIB Mundial),18 pertenecen a América Latina, siendo México el país más visitado y con más 32 millones de visitas anuales, según el Informe del Foro Económico Mundial de México, este se mantiene como el destino turístico favorito del continente (Mundo, 2017). En Nicaragua el turismo se ha convertido en un nuevo rubro económico. Según, El Boletín de Estadísticas de Turismo de INTUR (2017), este sector contribuyó con el 33% de los ingresos en divisas generadas por los principales productos de exportación a nivel nacional, ocupando de esta manera el primer lugar en los años 2015, 2016, y 2017, diversificando la economía nacional (INTUR, 2017). La comercialización de los destinos ha permitido que cada año el turismo incremente, sin embargo, según datos del Banco Central de Nicaragua (BCN), estima que el sector sufrió una pérdida en divisas de 231 millones de dólares, debido a la situación actual del país, la nueva proyección para el 2019, en cuanto a ingresos generados por el turismo era de 693 millones de dólares, por el contrario en el 201

    Big Data en Educación III: recomendaciones personalizadas de actuación ante estudiantes en riesgo de abandono

    Get PDF
    En este proyecto se elaboran un conjunto de recomendaciones personalizadas para guiar la actuación del profesor con estudiantes que hayan sido detectados en riesgo de abandono de una asignatura o de la titulación en general. Con carácter previo, se desarrollan métodos estadísticos que permitan la detección del riesgo de abandono de un estudiante

    MAREJADAS RURALES Y LUCHA POR LA VIDA, VOL. I:CONSTRUCCIÓN SOCIOCULTURAL Y ECONÓMICA DEL CAMPO.

    Get PDF
    Este volumen incluye trabajos que abordan temáticas que demuestran que el campo es una construcción sociocultural, por lo tanto, el medio rural es diferenciado y está en constante cambio y adaptación a los procesos globales y locales. Son 19 trabajos divididos en dos secciones, la primera, denominada Nuevas dinámicas sociales, económicas y culturales en el medio rural, está compuesta por 8 capítulos, en esta sección se incluyen aquellos trabajos que analizan de manera concreta los cambios perceptibles en las relaciones rurales y en las actividades económicas; procesos como desagrarización y nuevas actividades económicas son abordados aquí, así como propuestas metodológicas para el estudio de lo rural considerando los cambios y adaptaciones que se registran en los territorios. La segunda sección, Resistencias y alternativas al modelo neoliberal en la producción agrícola y alimentaria, está integrada por 11 trabajos que abordan las diversas formas en que los campesinos y productores agrícolas resisten y se adaptan a los cambios globales y a las modificaciones de política pública, desde los mercados alternativos hasta la producción de nuevos cultivos que generan un mercado nuevo a su producción, hasta las resistencias y defensa de la milpa, las reflexiones que nos ofrecen dan idea de la diversidad de formas en que la vida campesina se mantiene a pesar de todos los embates.INSTITUTO DE CIENCIAS AGROPECUARIAS Y RURALES (ICAR), UNIVERSIDAD DE GUADALAJARA, EL COLEGIO DE MICHOACÁN A.C., CUCOSTA SUR GRANA, FACULTAD DE ESTUDIOS SUPERIORES ACATLÁN-UNAM, ECOSU

    Natural History of MYH7-Related Dilated Cardiomyopathy

    Full text link
    BACKGROUND Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described. OBJECTIVES We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression. METHODS We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 +/- 19.2 years) recruited from 29 international centers. RESULTS At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% +/- 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of <= 35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants. CONCLUSIONS MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation

    Ciencia Odontológica 2.0

    Get PDF
    Libro que muestra avances de la Investigación Odontológica en MéxicoEs para los integrantes de la Red de Investigación en Estomatología (RIE) una enorme alegría presentar el segundo de una serie de 6 libros sobre casos clínicos, revisiones de la literatura e investigaciones. La RIE está integrada por cuerpos académicos de la UAEH, UAEM, UAC y UdeG

    Mis casos clínicos de especialidades odontológicas

    Get PDF
    Libro que muestra la atención de casos clínicos particulares referente a las diferentes especialidades odontológicasLibro que muestra la atención de casos clínicos particulares referente a las diferentes especialidades odontológicasUniversidad Autónoma de Campeche Universidad Autónoma del Estado de Hidalgo Universidad Autónoma del Estado de Méxic

    Abstracts from the Food Allergy and Anaphylaxis Meeting 2016

    Get PDF

    Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

    Get PDF
    Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

    Circulating miRNome detection analysis reveals 537 miRNAS in plasma, 625 in extracellular vesicles and a discriminant plasma signature of 19 miRNAs in children with retinoblastoma from which 14 are also detected in corresponding primary tumors.

    No full text
    miRNAs regulate post-transcriptional gene expression in metazoans, and thus are involved in many fundamental cellular biological processes. Extracellular miRNAs are also found in most human biofluids including plasma. These circulating miRNAs constitute a long distance inter cellular communication system and are potentially useful biomarkers. High throughput technologies like microarrays are able to scan a complete miRNome providing useful detection scores that are underexplored. We proposed to answer how many and which miRNAs are detectable in plasma or extracellular vesicles as these questions have not yet been answered. We set out to address this knowledge gap by analyzing the mirRNome in plasma and corresponding extracellular vesicles (EVs) from 12 children affected by retinoblastoma (Rb) a childhood intraocular malignant tumor, as well as from 12 healthy similarly aged controls. We calculated an average of 537 detectable miRNAs in plasma and 625 in EVs. The most miRNA enriched compartment were EVs from Rb cases with an average of 656 detectable elements. Using hierarchical clustering with the detection scores, we generated broad detection mirnome maps and identified a plasma signature of 19 miRNAs present in all Rb cases that is able to discriminate cases from controls. An additional 9 miRNAs were detected in all the samples; within this group, miRNA-5787 and miRNA-6732-5p were highly abundant and displayed very low variance across all the samples, suggesting both are good candidates to serve as plasma references or normalizers. Further exploration considering participant's sex, allowed discovering 5 miRNAs which corresponded only to females and 4 miRNAs corresponding only to males. Target and pathway analysis of these miRNAs revealed hormonal function including estrogen, thyroid signaling pathways and testosterone biosynthesis. This approach allows a comprehensive unbiased survey of a circulating miRNome landscape, creating the possibility to define normality in mirnomic profiles, and to locate where in these miRNome profiles promising and potentially useful circulating miRNA signatures can be found

    Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

    Get PDF
    Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P = .03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P = .09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P = .7) and major bleeding (0.8% and 0.9%, respectively; P = .9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population
    corecore